"10.1371_journal.pone.0131473","plos one","2015-07-08T00:00:00Z","Jens Minnerup; Heike Wersching; Michael Unrath; Klaus Berger","Department of Neurology, University of Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany; Institute of Epidemiology and Social Medicine, University of Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany","Conceived and designed the experiments: JM HW MU KB. Performed the experiments: JM HW MU KB. Analyzed the data: JM HW MU KB. Wrote the paper: JM HW MU KB.","Dr. Berger has received investigator-initiated research funding as principal or coordinating investigator in the areas of stroke, diabetes, depression and subclinical atherosclerosis, multimorbidity and health services research from the German Ministry of Research and Technology (BMBF). In addition, for the conduction (2003–2006) of a study on regional variations of migraine and other types of headache he has received unrestricted grants to the University of Muenster from the German Migraine and Headache Society and a consortium with equal shares formed by Allmiral, Astra-Zeneca, Berlin-Chemie, Boehringer Ingelheim Pharma, Boots Healthcare, GlaxoSmithKline, Janssen Cilag, McNeil Pharmaceuticals, MSD Sharp & Dohme, Pfizer. For a study on the Course of Restless Legs Syndrome (2008–2013) he has received unrestricted grants to the University of Muenster from the German Restless Legs Society and a consortium formed by Boehringer Ingelheim Pharma, Mundipharma Research, Neurobiotec, UCB Germany and Switzerland, Vifor Pharma and Roche Pharma. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2015","07","Jens Minnerup","JM",4,TRUE,4,4,4,4,TRUE,TRUE,FALSE,0,NA,FALSE
